Skip to main content

Table 1 Characteristics of the patients included in this study

From: The effects of obesity, diabetes and metabolic syndrome on the hydrolytic enzymes of the endocannabinoid system in animal and human adipocytes

  ‘Healthy’ (n = 6) Metabolic syndrome (n = 12) Diagnosed T2D (n = 10)
Gender split (male: female) 0:6 3:8 2:8
Age (years) 44.0 ± 4.7 44.5 ± 3.3 45.5 ± 2.7
BMI (kg.m -2 ) 44.0 ± 4.7 46.3 ± 1.7 44.8 ± 1.5
Insulin (mU.L -1 ) 12.2 ± 3.1 14.0 ± 2.3 15.9 ± 1.9
Glucose (mmol.L -1 ) 5.0 ± 0.2~ 5.1 ± 0.2* 8.7 ± 1.4~*
HbA1c (%) 5.8 ± 0.1 5.8 ± 0.3# 7.9 ± 0.7†#
HOMA2-%S 85.8 ± 26.2 71.4 ± 14.2 50.4 ± 6.8
MAP (mmHg) 96.1 ± 4.8 96.3 ± 4.3 104.8 ± 3.6
Dyslipidaemia medication 1 (statin) 1 (statin) 2 (statin)
Hyperglycaemia medication 0 0 5 (metformin)
Hypertension medication 3 (1: ACE inhibitor; 2: ACE inhibitor + thiazide diuretic) 3 (1: ACE inhibitor; 1: ACE inhibitor + β1 antagonist; 1: ACE inhibitor + thiazide diuretic) 3 (2: ACE inhibitor; 1: thiazide diuretic)
  1. Values are given as mean ± S.E.M. ~*†#Values marked with the same characters are significantly different from each other (P < 0.05). Data analysed using ANOVA and Bonferroni post hoc test.